UCSF Diabetes Center, University of California at San Francisco, San Francisco, California 94143, USA.
Cold Spring Harb Perspect Med. 2012 Mar;2(3):a007807. doi: 10.1101/cshperspect.a007807.
Type 1 Diabetes (T1D), also called juvenile diabetes because of its classically early onset, is considered an autoimmune disease targeting the insulin-producing β cells in the pancreatic islets of Langerhans. T1D reflects a loss of tolerance to tissue self-antigens caused by defects in both central tolerance, which aims at eliminating potentially autoreactive lymphocytes developing in the thymus, and peripheral tolerance, which normally controls autoreactive T cells that escaped the thymus. Like in other autoimmune diseases, the mechanisms leading to T1D are multifactorial and depend on a complex combination of genetic, epigenetic, molecular, and cellular elements that result in the breakdown of peripheral tolerance. In this article, we discuss the contribution of these factors in the development of the autoimmune response targeting pancreatic islets in T1D and the therapeutic strategies currently being explored to correct these defects.
1 型糖尿病(T1D),也称为青少年糖尿病,因为其典型的发病年龄较早,被认为是一种自身免疫性疾病,针对的是胰岛中的胰岛素产生β细胞。T1D 反映了对组织自身抗原的耐受性丧失,这是由中枢耐受缺陷引起的,中枢耐受旨在消除在胸腺中发育的潜在自身反应性淋巴细胞,以及外周耐受缺陷,通常控制逃避免疫的自身反应性 T 细胞胸腺。与其他自身免疫性疾病一样,导致 T1D 的机制是多因素的,取决于遗传、表观遗传、分子和细胞因素的复杂组合,这些因素导致外周耐受的破坏。在本文中,我们讨论了这些因素在 T1D 中针对胰岛的自身免疫反应发展中的贡献,以及目前正在探索的纠正这些缺陷的治疗策略。